Home > Insider Trading > Ascendis Pharma A/s > Profile

Ascendis Pharma A/s (ASND)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Hedge Fund Popularity

Display

13F filing is ongoing

Display Share Price

Display Large Version

Hedge Fund Holdings

Filing Period:

Last updated on August 24, 2022, 2:22 pm based on SEC 13F filings Last update: August 24, 2022, 2:22 pm

No.	Hedge Fund	Shares	Value (x$1000)	Activity	% Port
1.	RA Capital Management Peter Kolchinsky	7,567,900	$703,512		18.75%
2.	Baker Bros. Advisors Julian Baker And Felix Baker	4,852,655	$451,103	+7%	2.55%
3.	VenBio Select Advisor Kurt Von Emster	2,275,000	$211,484	+4%	4.17%
4.	Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail	425,500	$39,554	+2%	1.15%
5.	Adage Capital Management Phill Gross And Robert Atchinson	165,000	$15,338	-5%	0.03%

Institutional Investors' Holdings

Filing Period:

No.	Name	Shares	Value (x$1000)	% Port
1.	Advisornet Financial, Inc	0	$0	0%

News See All

Here's Why Ascendis Pharma A/S (ASND) Became a Detractor in Artisan Partners' Portfolio

Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter investor letter. A copy of the same can be downloaded here.

Keep Reading →

September 27th, 2022 - Hedge Fund Investor Letters News

Artisan Partners 'Remains Quite Optimistic' in Ascendis Pharma (ASND)

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here.

Keep Reading →

February 25th, 2022 - Hedge Fund Investor Letters News

Hedge Funds Are Dumping Ascendis Pharma A/S (ASND)

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.

Keep Reading →

December 11th, 2021 - Hedge Funds News

5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky's RA Capital

In this piece, we will take a look at the top 5 pharmaceutical stocks to buy according to Peter Kolchinsky's RA Capital. If you want a comprehensive view of Dr.

Keep Reading →

November 25th, 2021 - Hedge Funds News

Here's Why Artisan Partners Increased its Ascendis Pharma (ASND) Position

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ third quarter 2021 investor letter – a copy of which can be downloaded here.

Keep Reading →

November 23rd, 2021 - Hedge Fund Investor Letters News

Here is What Hedge Funds Think About Ascendis Pharma A/S (ASND)

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...

Keep Reading →

October 18th, 2021 - Hedge Funds News

Is Ascendis Pharma A/S (ASND) A Good Stock To Buy?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.

Keep Reading →

July 12th, 2021 - Hedge Funds News

Should You Consider Investing in Ascendis Pharma (ASND)?

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ first quarter 2021 investor letter – a copy of which can be downloaded here.

Keep Reading →

May 6th, 2021 - Hedge Fund Investor Letters News

Is ASND Stock A Buy or Sell?

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their...

Keep Reading →

April 19th, 2021 - Hedge Funds News